Sunday, June 26, 2022
June 26, 2022

Linkedin Pinterest

Clark County, Washington bullish on biotech industry

Emerging sector worth $30 billion in Washington

By , Columbian Innovation Editor
Published:

Vancouver’s medical biotech companies — Absci, CytoDyn and a new player, Capsigen — are on the leading edge of a global revolution aimed at developing new technologies to produce medicines and tools for gene therapy.

Biotech, or life sciences companies, are a relatively new industry, but they already represent a $30 billion business in Washington.

In 2021 alone, the industry reported record investments, with companies raising almost $5 billion — including initial stock offerings for six life science companies, according to a news release from Life Science Washington.

Also, from 2015-2019, the industry experienced 23.5 percent job growth, outpacing both Washington private-sector job growth and life science job growth nationally, according to the news release.

Absci held its IPO in July of last year and then moved into a new headquarters, and it was valued at about $2 billion. Its work includes engineering E. coli microorganisms to produce proteins to create drugs, including insulin. Absci claims it can lower the cost of goods by 75 percent and allow pharmaceutical companies to get drugs to market one to two years earlier.

Biosciences

Research associate Hayley Carter works in the lab at Absci doing DNA sequencing sample preparation. Clark County, Washington bullish on biotech industry
Vancouver’s medical biotech companies — Absci, CytoDyn and a new player, Capsigen — are on the leading edge of a global revolution aimed at developing…
Riffat Ahmed checks the quality of samples in Capsigen's downtown Vancouver lab. At top, AAV capsids have the potential to deliver gene therapy tools directly to specific cells to cure diseases that currently have no cure. Can harmless viruses target only cells that need treatment? Vancouver’s Capsigen says yes
Can harmless viruses target only the cells that need treatment? Vancouver company says yes.

“I think the county’s biotech future is bright, and we at Absci look forward to helping establish this region as a thriving biotech hub in the years to come,” said Sean McClain, founder and CEO at Absci.

“Vancouver, Clark County, and Washington broadly have been really supportive of Absci’s growth,” McClain said. “There are leaders here who are committed to helping emerging biotech companies develop, grow the workforce, expand the area’s technology footprint, and ultimately improve lives for patients with health care innovations.”

CytoDyn, a Vancouver biotech company, is creating treatments for diseases using an antibody called Leronlimab. The company was founded in 2002, and it’s now searching for a new CEO a year after the company was sued and a board takeover attempt by shareholder activists failed.

Still, the company remains bullish over the future of Leronlimab.

“Our target, the CCR5 receptor, has been implicated in multiple disease processes from HIV, GVHD, NASH, stroke recovery, multiple sclerosis, Parkinson’s disease, to metastatic cancer. Leronlimab, our CCR5 antagonist, is a once a week, subcutaneous injection. One molecule with multiple opportunities,” CytoDyn’s website states.

Capsigen, which incorporated last year, is engineering a virus component called an AAV capsid, which acts as a vehicle to deliver a therapeutic gene to specific cells to cure certain diseases.

Vancouver-based biotech companies

Absci

18105 S.E. Mill Plain Blvd., Vancouver

Founded 2011

Engineers microorganisms called E. coli to produce proteins for pharmaceutical companies that use them to efficiently manufacture drugs, including insulin.

www.absci.com

CytoDyn

1111 Main St. Ste. 660, Vancouver

Founded 2002

Creating treatments for diseases using an antibody called Leronlimab.

www.cytodyn.com

Capsigen

1010 Washington St., Vancouver

Founded 2021

Engineers AAV capsids to deliver therapeutic genes to targeted tissues.

capsigen.com

“It’s a one-time treatment,” Capsigen co-founder Dr. Hiroyuki Nakai said. That’s compared to current treatments for some diseases that require medication for the remainder of the patient’s life.

The company has 12 employees and plans to double that by year’s end.

Support local journalism

Your tax-deductible donation to The Columbian’s Community Funded Journalism program will contribute to better local reporting on key issues, including homelessness, housing, transportation and the environment. Reporters will focus on narrative, investigative and data-driven storytelling.

Local journalism needs your help. It’s an essential part of a healthy community and a healthy democracy.

Community Funded Journalism logo
Loading...